Stifel Financial
CHRS icon

Stifel Financial’s Coherus Oncology CHRS Stock Holding History

Stifel Financial’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-49,925
Closed -$119K – 3377
2024
Q1 		$119K Sell
49,925
-4,476
-8% -$11K ﹤0.01% 3179
2023
Q4 		$181K Sell
54,401
-15,718
-22% -$42.1K ﹤0.01% 3079
2023
Q3 		$262K Buy
+70,119
New +$324K ﹤0.01% 2862
2018
Q3 		– Sell
-38,806
Closed -$544K – 2759
2018
Q2 		$544K Buy
+38,806
New +$555K ﹤0.01% 1990

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stifel Financial's CHRS Position: Q2 2024 in Review

Stifel Financial sold out of Coherus Oncology (CHRS) in Q2 2024, closing a stake of 49,925 shares — an estimated $119K sold.

Stifel Financial first reported a position in CHRS in Q2 2018 and held it in 4 quarters. The position peaked at $544K in Q2 2018. 135 funds tracked by Wall St. Rank hold CHRS as of Q2 2024.

  • Stifel Financial reported no remaining Coherus Oncology position as of Q2 2024 after selling out during the quarter.
  • Stifel Financial sold 49,925 Coherus Oncology shares in Q2 2024, an estimated $119K.
  • Stifel Financial first reported a position in Coherus Oncology in Q2 2018 and held it in 4 quarters.
  • Stifel Financial's Coherus Oncology position peaked at $544K in Q2 2018.
  • 135 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2024.

Based on Stifel Financial's 13F filing for Q2 2024, filed 13 Aug 2024.